Tourmaline Bio Inc, formerly Talaris Therapeutics Inc, is a biotechnology company focused on developing transformative cell therapies to address life-threatening diseases and improve the lives of patients. The company was founded in 2016 as a spinoff from the University of Louisville and was previously known as Regenerex LLC. Talaris is headquartered in Louisville, Kentucky, USA.
The primary goal of Talaris Therapeutics is to develop an allogeneic cell therapy called FCR001, which involves the use of regulatory T cells (Tregs) to induce immune tolerance in organ transplant recipients. This innovative approach aims to reduce the need for lifelong immunosuppression after transplantation, which can have significant side effects and long-term health risks. By modulating the immune response, Talaris' therapy aims to allow patients to maintain the transplanted organ without the risks associated with chronic immunosuppression.
Talaris Therapeutics is conducting clinical trials to evaluate the safety and efficacy of its cell therapy in kidney transplant recipients. The company has received significant support from investors, including funding from biotech-focused venture capital firms and strategic partnerships.
Talaris' work in the field of cell therapy represents an exciting advancement in the treatment of organ transplant patients. If successful, their approach could potentially revolutionize organ transplantation and improve the long-term outcomes for transplant recipients, offering hope to those awaiting life-saving transplants.